Please assess the completion status of the following clinical trial:

Trial Title: Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.~* Severity of psoriasis disease meeting all of the following three criteria:~  * Psoriasis Area and Severity Index (PASI) score of 12 or greater~ * Investigator's Global Assessment (IGA) score of 3 or greater~ * Total body surface area (BSA) affected of 10% or greater~* Inadequate control by prior use of topical treatment, phototherapy and/or systemic therapy.~Exclusion criteria:~* Current forms of psoriasis other than chronic plaque-type psoriasis (for example, pustular, erythrodermic, guttate).~* Current drug-induced psoriasis.~* Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.~* Significant medical problems such as uncontrolled hypertension, congestive heart failure or a condition that significantly immunocompromises the subject.~* Hematological abnormalities.~* History of an ongoing, chronic or recurrent infectious disease, or evidence of untreated tuberculosis.~* History of lymphoproliferative disease or history of malignancy of any organ system within the past 5 years.~* Pregnant or nursing (lactating) women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects who were in placebo at Week 52 cannot continue in the extension treatment period
- Secukinumab 150 mg (Type: EXPERIMENTAL): After the data base lock of week 52 data has been performed, subjects received secukinumab 150 mg treatment as open label for the remainder of the extension treatment period.
- Secukinumab 300 mg (Type: EXPERIMENTAL): After the data base lock of week 52 data has been performed, subjects received secukinumab 300 mg treatment as open label for the remainder of the extension treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).